Skip to content
← Full study record

NCT04816526 · MORE INFO

Limitations, agreements, and source contact

Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy · Source last updated 2024-10-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
point Of Contact
email
milos@cartesiantx.com
organization
Cartesian Therapeutics
phone
4436335855
title
Dr. Milos Miljkovic, Chief Medical Officer
Complete source fields
certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
point Of Contact
email
milos@cartesiantx.com
organization
Cartesian Therapeutics
phone
4436335855
title
Dr. Milos Miljkovic, Chief Medical Officer

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice